Safety of nintedanib plus docetaxel in advanced non-squamous NSCLC (nsNSCLC) patients: The preliminary results of the SENECA (second-line nintedanib in non-small cell lung cancer) trial

A. M. Morelli; M. R. Migliorino; A. Morabito; R. Chiari; F. Grossi; P. Bordi; F. Di Costanzo; A. Delmonte; G. Romano; A. Misino; V. Scotti; V. Gregorc; S. Pisconti; G. L. Ceresoli; A. Del Conte; I. Colantonio; L. Ciuffreda; E. Capelletto; I. Stura; S. Novello

doi:10.1093/annonc/mdy292.026

Safety of nintedanib plus docetaxel in advanced non-squamous NSCLC (nsNSCLC) patients: The preliminary results of the SENECA (second-line nintedanib in non-small cell lung cancer) trial

A. M. Morelli, M. R. Migliorino, A. Morabito, R. Chiari, F. Grossi, P. Bordi, F. Di Costanzo, A. Delmonte, G. Romano, A. Misino, V. Scotti, V. Gregorc, S. Pisconti, G. L. Ceresoli, A. Del Conte, I. Colantonio, L. Ciuffreda, E. Capelletto, I. Stura, S. Novello

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	viii506-viii507
Journal	Annals of oncology : official journal of the European Society for Medical Oncology
Volume	29
DOIs	https://doi.org/10.1093/annonc/mdy292.026
Publication status	Published - Oct 1 2018

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1093/annonc/mdy292.026

Cite this

Morelli, A. M., Migliorino, M. R., Morabito, A., Chiari, R., Grossi, F., Bordi, P., Di Costanzo, F., Delmonte, A., Romano, G., Misino, A., Scotti, V., Gregorc, V., Pisconti, S., Ceresoli, G. L., Del Conte, A., Colantonio, I., Ciuffreda, L., Capelletto, E., Stura, I., & Novello, S. (2018). Safety of nintedanib plus docetaxel in advanced non-squamous NSCLC (nsNSCLC) patients: The preliminary results of the SENECA (second-line nintedanib in non-small cell lung cancer) trial. Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii506-viii507. https://doi.org/10.1093/annonc/mdy292.026

Safety of nintedanib plus docetaxel in advanced non-squamous NSCLC (nsNSCLC) patients : The preliminary results of the SENECA (second-line nintedanib in non-small cell lung cancer) trial. / Morelli, A. M.; Migliorino, M. R.; Morabito, A.; Chiari, R.; Grossi, F.; Bordi, P.; Di Costanzo, F.; Delmonte, A.; Romano, G.; Misino, A.; Scotti, V.; Gregorc, V.; Pisconti, S.; Ceresoli, G. L.; Del Conte, A.; Colantonio, I.; Ciuffreda, L.; Capelletto, E.; Stura, I.; Novello, S.

In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, 01.10.2018, p. viii506-viii507.

Research output: Contribution to journal › Article › peer-review

Morelli, AM, Migliorino, MR, Morabito, A, Chiari, R, Grossi, F, Bordi, P, Di Costanzo, F, Delmonte, A, Romano, G, Misino, A, Scotti, V , Gregorc, V, Pisconti, S, Ceresoli, GL, Del Conte, A, Colantonio, I, Ciuffreda, L, Capelletto, E, Stura, I & Novello, S 2018, 'Safety of nintedanib plus docetaxel in advanced non-squamous NSCLC (nsNSCLC) patients: The preliminary results of the SENECA (second-line nintedanib in non-small cell lung cancer) trial', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 29, pp. viii506-viii507. https://doi.org/10.1093/annonc/mdy292.026

Morelli AM, Migliorino MR, Morabito A, Chiari R, Grossi F, Bordi P et al. Safety of nintedanib plus docetaxel in advanced non-squamous NSCLC (nsNSCLC) patients: The preliminary results of the SENECA (second-line nintedanib in non-small cell lung cancer) trial. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Oct 1;29:viii506-viii507. https://doi.org/10.1093/annonc/mdy292.026

Morelli, A. M. ; Migliorino, M. R. ; Morabito, A. ; Chiari, R. ; Grossi, F. ; Bordi, P. ; Di Costanzo, F. ; Delmonte, A. ; Romano, G. ; Misino, A. ; Scotti, V. ; Gregorc, V. ; Pisconti, S. ; Ceresoli, G. L. ; Del Conte, A. ; Colantonio, I. ; Ciuffreda, L. ; Capelletto, E. ; Stura, I. ; Novello, S. / Safety of nintedanib plus docetaxel in advanced non-squamous NSCLC (nsNSCLC) patients : The preliminary results of the SENECA (second-line nintedanib in non-small cell lung cancer) trial. In: Annals of oncology : official journal of the European Society for Medical Oncology. 2018 ; Vol. 29. pp. viii506-viii507.

@article{cfcb833553bf4f5ca588c19af4a203c3,

title = "Safety of nintedanib plus docetaxel in advanced non-squamous NSCLC (nsNSCLC) patients: The preliminary results of the SENECA (second-line nintedanib in non-small cell lung cancer) trial",

author = "Morelli, {A. M.} and Migliorino, {M. R.} and A. Morabito and R. Chiari and F. Grossi and P. Bordi and {Di Costanzo}, F. and A. Delmonte and G. Romano and A. Misino and V. Scotti and V. Gregorc and S. Pisconti and Ceresoli, {G. L.} and {Del Conte}, A. and I. Colantonio and L. Ciuffreda and E. Capelletto and I. Stura and S. Novello",

year = "2018",

month = oct,

day = "1",

doi = "10.1093/annonc/mdy292.026",

language = "English",

volume = "29",

pages = "viii506--viii507",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "NLM (Medline)",

}

TY - JOUR

T1 - Safety of nintedanib plus docetaxel in advanced non-squamous NSCLC (nsNSCLC) patients

T2 - The preliminary results of the SENECA (second-line nintedanib in non-small cell lung cancer) trial

AU - Morelli, A. M.

AU - Migliorino, M. R.

AU - Morabito, A.

AU - Chiari, R.

AU - Grossi, F.

AU - Bordi, P.

AU - Di Costanzo, F.

AU - Delmonte, A.

AU - Romano, G.

AU - Misino, A.

AU - Scotti, V.

AU - Gregorc, V.

AU - Pisconti, S.

AU - Ceresoli, G. L.

AU - Del Conte, A.

AU - Colantonio, I.

AU - Ciuffreda, L.

AU - Capelletto, E.

AU - Stura, I.

AU - Novello, S.

PY - 2018/10/1

Y1 - 2018/10/1

UR - http://www.scopus.com/inward/record.url?scp=85081529478&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85081529478&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy292.026

DO - 10.1093/annonc/mdy292.026

M3 - Article

C2 - 32137308

VL - 29

SP - viii506-viii507

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

ER -

Safety of nintedanib plus docetaxel in advanced non-squamous NSCLC (nsNSCLC) patients: The preliminary results of the SENECA (second-line nintedanib in non-small cell lung cancer) trial

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this